Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Engh, R. A.
Right arrow Articles by Bossemeyer, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Engh, R. A.
Right arrow Articles by Bossemeyer, D.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Volume 271, Number 42, Issue of October 18, 1996 pp. 26157-26164
©1996 by The American Society for Biochemistry and Molecular Biology, Inc.

Crystal Structures of Catalytic Subunit of cAMP-dependent Protein Kinase in Complex with Isoquinolinesulfonyl Protein Kinase Inhibitors H7, H8, and H89
STRUCTURAL IMPLICATIONS FOR SELECTIVITY*

(Received for publication, April 22, 1996, and in revised form, July 25, 1996)

Richard A. Engh Dagger , Andreas Girod , Volker Kinzel , Robert Huber Dagger and Dirk Bossemeyer §

From the Dagger  Abteilung Strukturforschung II, Max-Planck Institute for Biochemistry, D-82152 Martinsried and the Department for Pathochemistry, German Cancer Research Center, D-69120 Heidelberg, Federal Republic of Germany

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
FOOTNOTES
Acknowledgments
REFERENCES


ABSTRACT

The discovery of several hundred different protein kinases involved in highly diverse cellular signaling pathways is in stark contrast to the much smaller number of known modulators of cell signaling. Of these, the H series protein kinase inhibitors (1-(5-isoquinolinesulfonyl)-2-methylpiperazine (H7), N-[2-(methylamino)ethyl]-5-isoquinolinesulfonamide (H8) N-[2-(p-Bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H89)) are frequently used to block signaling pathways in studies of cellular regulation. To elucidate inhibition mechanisms at atomic resolution and to enable structure-based drug design of potential therapeutic modulators of signaling pathways, we determined the crystal structures of corresponding complexes with the cAPK catalytic subunit. Complexes with H7 and H8 (2.2 Å) and with H89 (2.3 Å) define the binding mode of the isoquinoline-sulfonamide derivatives in the ATP-binding site while demonstrating effects of ligand-induced structural change. Specific interactions between the enzyme and the inhibitors include the isoquinoline ring nitrogen ligating to backbone amide of Val-123 and an inhibitor side chain amide bonding to the backbone carbonyl of Glu-170. The conservation of the ATP-binding site of protein kinases allows evaluation of factors governing general selectivity of these inhibitors among kinases. These results should assist efforts in the design of protein kinase inhibitors with specific properties.


INTRODUCTION

Isoquinolinesulfonamide protein kinase inhibitors of the H series are among the most widely used inhibitors of Ser/Thr kinases and are indispensable in cellular and signal transduction research. Protein phosphorylation (central to cellular regulation) is mediated by the individual action of several hundred different protein kinases. Recent progress in the understanding of the highly complex cellular signaling networks depends largely on the availability and quality of specific agents that interfere with the pathways under investigation. The usefulness of a protein kinase inhibitor is defined by its ability to permeate cell membranes, its solubility, and its relative degree of specificity. Each year hundreds of publications describe work using isoquinolinesulfonamide inhibitors, despite the fact that the mode of specific inhibition by these compounds is not completely understood.

We have used the cAMP-dependent protein kinase (cAPK),1 which binds many H series inhibitors, as a model system to investigate the factors governing inhibitor binding and specificity. Three of the most frequently used members of this class are H7, H8 (1), and H89 (2) (Fig. 1). They all act in competition to ATP but not to substrate. The highest selectivity and affinity is found with H89, which has a Ki of 48 nM for cAPK, whereas H8 has a moderate affinity for both cGPK and cAPK, and H7 inhibits protein kinase C in addition to cGPK and cAPK (Table I). The inhibitors have enabled assignment of specific roles of these protein kinases in numerous regulatory interrelations (3, 4, 5, 6, 7, 8). They are, however, not only valuable for the cell biologist. Pharmacologists are increasingly interested in the possibility of interfering with cellular signaling, especially in the area of anticancer drug discovery. There is evidence that isoquinolinesulfonyl inhibitors may be promising in this field (9, 10, 11, 12, 13, 14).


Fig. 1. H series inhibitors and ATP.
[View Larger Version of this Image (12K GIF file)]

Table I.

Inhibitory constants of H series protein kinase inhibitors

cGPK, cGMP-dependent protein kinase; MLCK, myosin light chain kinase; PKC, protein kinase C; CK-1, protein kinase CK-1, CK-2, protein kinase CK-2.
Compound KiM)
Ref.
cGPK cAPK MLCK PKC CK-1 CK-2

1-(3-Isoquinollnesulfonyl)-2-methylpiperazine (H7) 5.8 3.0 97 6.0 100 780 1
N-[2-(Methylamino)ethyl]-5-isoquinolinesulfonamide (H8) 0.48 1.2 68 15 133 950 1
N-[2-(p-Bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H89) 0.48 ± 0.13 0.048 ±0.008 28.3 ± 17.5 31.7 ± 15.9 38.3 ± 6.0 136.7 ± 17.0 2

Recently, crystal structures from several different protein kinases have been solved (for review see Refs. 15, 16, 17, 18, 19). The structures confirmed not only the high degree of structural conservation of the highly homologous catalytic kinase core (20) but simultaneously showed how subtle differences are responsible for individual properties of protein kinases. Most of the residues that are highly conserved or invariant in the protein kinase family line the active site, and many of them interact with ATP (21, 22). Despite high similarity of Km values for ATP binding among protein kinases, the H inhibitors have remarkably different Ki values. The crystal structures of kinase bound inhibitor molecules described here now show the mode of inhibitory action and the factors governing selectivity and will provide a firm basis for the design of new protein kinase inhibitors.


EXPERIMENTAL PROCEDURES

Protein Expression and Purification

Expression vector pT7-7 was used to express the bovine Calpha catalytic subunit (23) in strain Escherichia coli BL21(DE3). Cells grown in LB medium (50 mg/liter ampicillin) were induced at 0.6 OD660 by addition of 0.4 mM isopropyl-beta -D-galactopyranoside for 16 h at 23 °C. The cells were collected and sonified in 30 mM MES, 50 mM KCl, 1 mM EDTA, 1 mM dithiothreitol. For affinity purification (24), the supernatant of a 45 min, 30,000 × g centrifugation was made 2 mM MgATP, 0.1% Chaps and applied to a column with agarose bound protein kinase inhibitor peptide PKI-(5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24). After washing with 50 mM and 200 mM NaCl in 20 mM Tris-HCl, 2 mM MgCl2, 0.1% Chaps, 400 µM ATP, pH 7.4, about 10 mg of crude catalytic subunit per liter of cell culture eluted in 200 mM arginine, 50 mM NaCl, 1 mM EDTA, 20 mM Tris-HCl, pH 7.4. The recombinant kinase was fully active compared with enzyme from bovine heart. The enzyme was diluted 5-fold in H2O and applied to a Mono-S 10/10 FPLC column for separation of differently phosphorylated fractions (25) using a LiCl gradient from 0 to 300 mM in 25 mM BisTris-propane, pH 8.5. The identity of the samples was confirmed by electrospray mass spectrometry.

Protein Crystallization

Hanging droplets containing 20 mg/ml protein, 25 mM Mes-BisTris, 75 mM LiCl, 0.1 mM EDTA, 1 mM dithiothreitol, 1.5 mM octanoyl-N-methylglucamide (26), 1.5 mM H inhibitor, and 1 mM PKI-(5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24), pH 6.3 to 6.6, were equilibrated at 5 °C against 15% methanol. After 1-3 days crystals were harvested into similar buffer, containing 1 µM inhibitor, 0.1 µM PKI-(5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24), and 25% methanol. In each case one crystal was sufficient to obtain a complete data set.

X-ray Diffraction and Crystal Structure Analysis

X-ray diffraction were collected with a Siemens X1000 area detector using a copper target Rigaku Rotaflex x-ray generator and graphite crystal Kalpha monochromator. Data collection and evaluation were done using the SIEMENS suite of programs, including FRAMBO, ASTRO, and SAINT. All crystals had P212121 symmetry with cell constants near (73.4, 76.2, 80.5); H89-cAPK·PKI deviated somewhat with cell constants (73.6, 77.2, 80.3). Nominally complete data sets to 2.2 Å (Rsym ~6%) ranged from 63 (H7-cAPK·PKI) to 77% (H8-cAPK·PKI-(peak II)) completeness after applying a 3sigma /fobs cutoff during refinement. Model refinement was done using XPLOR (27) with kinase coordinates 1cdk (22) after fitting to coordinates 2cpk (29) of the Brookhaven Data Bank (29) as initial model. Model building and refinement concentrated on the inhibitor and binding region; Rfree was not used, with a cutoff of 6 Å to minimize bulk solvent distortion. Only those solvent molecules in and around the binding region were modeled. Model building and graphical modeling was done with the program O (31). The final R factors for the models with inhibitor and active site water molecules (18-21 molecules) ranged from 18.8 to 19.9% (Table II).2

Table II.

Crystallographic refinement


Crystal H7-cAPK · PKI H8-cAPK · PKI(I) H8-cAPK · PKI(II) H89-cAPK · PKI

Cell dimensions 73.57, 76.32, 80.56 73.4, 76.2, 80.5 73.38, 76.20, 80.52 73.63, 77.21, 80.27 
Final R-factor 18.8% 20.9% 19.9% 19.4%
Total no. of unique reflections in refinement (3sigma ) 14,158 15,590 17,182 12,157
Resolution range, completeness: 6.0-2.2 63% 70% 77% 62%
Highest resolution shell, completeness: 2.20-2.29 (*2.3-2.39) 32% 39% 51% 26%a
Bond, angle deviations 0.016 Å, 2.2 ° 0.014 Å, 1.9 ° 0.013 Å, 1.8 ° 0.013 Å, 1.9 °
Rsym 6.0% 6.5% 5.7% 5.8%
Total, atoms: water 2973  (18) 2953  (0) 2974  (21) 2983  (21)


RESULTS AND DISCUSSION

Overall Structure

Several crystal structures of recombinant mouse or native porcine catalytic subunit of the cAMP-dependent protein kinase (cAPK) have been described, in binary complex with peptide inhibitor PKI-(5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24) (28), in ternary complexes with additional MgATP or MnAMP-PNP, and in the unbound apo form (21, 22, 29, 32). The structures showed nucleotide and substrate binding and the mechanism of phosphotransfer. We have determined four crystal structures of the bovine recombinant catalytic subunit of cAPK in complex with the protein kinase inhibitors H7, H8, or H89 and the pseudosubstrate inhibitor peptide PKI-(5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24) (H7-cAPK·PKI, H8-cAPK·PKI, H89-cAPK·PKI). The peptide inhibitor will be referred to as ``pseudosubstrate'' or ``PKI'' in the following to avoid confusion with the H series inhibitors. Mass spectrometry of differently phosphorylated enzyme populations confirmed 4 mol (peak I) and 3 mol of phosphate (peak II) per mol of enzyme (25). H8 was co-crystallized with both peak I and peak II enzyme and H7 and H89 with peak II enzyme only. The phosphorylation of Ser-139 in peak I enzyme, in addition to phosphorylation of Thr-197 and Ser-338 in both peaks I and II, agrees with previous measurements (33).

The overall structures of all three H inhibitor complexes of the bovine enzyme conform to the known ternary complex with PKI and ATP or AMP-PNP (AMPPNP-cAPK·PKI); the differing degrees of autophosphorylation in the two H8 co-crystals had no apparent other structural consequences. In the nucleotide bound form, the ATP molecule occupies the cleft between the two lobes that contains the active site, with the adenine base well buried and the gamma -phosphate facing the peptide (pseudo)-phosphorylation site. The inhibition kinetics of H inhibitors with respect to MgATP (1) suggest competition at the ATP-binding site; this is confirmed in all crystal structures as the isoquinoline sulfonyl moieties mimic adenosine binding.

Unbound cAPK can adopt an open conformation, resulting from a rotation of the upper lobe relative to the lower lobe (32) (orientation of Fig. 2). In all H inhibitor co-crystals the enzyme is in an essentially closed conformation (Fig. 2) with two differences: a very small rotation of the N lobe by 2° toward a slightly more open conformation compared with the AMPPNP-cAPK·PKI structure, and a large variability of the conformation of the first two beta -strands in the region of the glycine flap (Gly-50 to Val-57). This glycine flap has sequence similarity to glycine loop motifs of other nucleotide binding proteins but is structurally unique (34). In the H7-cAPK·PKI and H8-cAPK·PKI co-crystals, it partially occupies at least two positions.


Fig. 2. Secondary structure of bovine cAPK catalytic subunit in complex with H7 and PKI-(5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24). DI24 marks the peptide C terminus. (Drawn with MOLSCRIPT (48).)
[View Larger Version of this Image (85K GIF file)]

Pseudosubstrate Binding

The conformation of the pseudosubstrate PKI-(5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24) in the inhibitor co-crystals differs somewhat from the ternary complexes with nucleotide. Arg-I18, part of the substrate recognition consensus sequence, has a new side chain orientation. In the AMPPNP-cAPK·PKI complex it interacts with the ribose 3'OH, Tyr-330, Glu-170, and with the carbonyl of Thr-51 in the glycine flap. In the H inhibitor co-crystal structures, the side chain of Arg-I18 points away from the cleft and forms hydrogen bonds with Glu-170 and Asp-328 (Fig. 3). Partial occupancy of the Arg-I18 side chain has been reported from a binary complex (26). Apparently, the presence of a nucleotide promotes formation of attractive contacts in this region. In contrast to the ternary AMPPNP-cAPK·PKI complex, every contact of the pseudosubstrate peptide to the N-lobe is lost, due to the new conformation of the glycine flap and a 0.9-Å displacement of the PKI pseudophosphorylation site away from the cleft. This is in support of the known synergism of PKI and nucleotide binding by this enzyme (3, 22, 35, 36). The absence of a direct interaction of the PKI with any of the inhibitor molecules excludes an active role of PKI in inhibitor binding. This is supported by identical KD (for free enzyme) and Ki (in the phosphorylation reaction) values of H8. PKI apparently contributes to crystal formation by providing crystal contacts (not shown).


Fig. 3. Conformational change of Arg-I18, residue of the basic subsite of the consensus substrate recognition sequence. Red dotted lines, contacts of PKI-(5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24) to the nucleotide (in green) and the glycine flap of the ternary MnAMP-PNP-cAPK·PKI complex (turquoise carbon atoms). Blue dotted lines, new contacts of the Arg-I18 side chain (blue carbon atoms) upon H inhibitor (not shown) binding to Asp-328.
[View Larger Version of this Image (22K GIF file)]

The Isoquinoline Binding Site

One of the intriguing aspects of H inhibitor binding to the protein kinase is the spatial congruence of the isoquinoline sulfonyl and sulfonamide groups with a bound adenosine (Fig. 4, A and B). A hydrogen bond between the Val-123 amide and the isoquinoline ring N-13 mimics one of the three H bonds to adenine (22). The isoquinolines provide many, and in the case of H7 and H8 most, of the Van der Waals contacts with enzyme residues (Table III), Val-57 and Ala-70, both almost invariant, Leu-49, Met-120, Glu-121, Tyr-122, Leu-173, Thr-183, and Phe-327. Val-104 is unique in having contacts with ATP in the corresponding complex but not with the inhibitor molecules. Inhibitor binding alters few side chain conformations; Met-120 is shifted 0.8 Å at the delta  sulfur, accommodating the larger isoquinoline rings, whereas Thr-183, which forms an H bond to the N-7 of adenine, adopts several conformations. In the H8-cAPK·PKI structures, Thr-183 shares a hydrogen bond with the carboxylate of Asp-184, which also is in a new conformation (Figs. 5 and 6).


Fig. 4. A, spatial structures of H inhibitors and MnAMP-PNP. Molecules as stick model, the bromine of H89 is shown as CPK model. Atom colors: white, carbon; blue, nitrogen; red, oxygen; yellow, sulfur; purple, bromine and manganese. B, congruence of H8 (yellow carbon atoms) and adenosine (white carbon atoms) after superposition of H8-cAPK·PKI and AMPPNP-cAPK·PKI.
[View Larger Version of this Image (66K GIF file)]

Table III.

Van der Waals contacts of adenosine and isoquinoline ring atoms to enzyme residues

p*, polar contact. Numbers include the number of polar contacts in brackets.
Residue H7 H8 H89 ATP

Leu-49 1 2 2 1
Val-57 2 5 3 6
Ala-70 5 4 4 4
Val-104 1
Met-120 1 1 1 2
Glu-121 1 1 2 1p*
Tyr-122 5 3 3 1
Val-123 3  (1p*) 4  (1p*) 6  (1p*) 1p*
Leu-173 7 6 5 5
Thr-183 3 3 6 5  (1p*)
Phe-327 4 4 3 2
Total 31  (1p*) 32  (1p*) 34  (1p*) 26  (3p*)


Fig. 5. Stereo representation of the inhibitor binding site of H8-cAPK·PKI. H bonds are depicted as dotted lines; the contact to Gly-50 amide is unfavorable.
[View Larger Version of this Image (26K GIF file)]


Fig. 6. Conformational flexibility of the glycine flap and ligand-induced conformational change. Superimposed are the refined models of H8-cAPK·PKI with upper (pink) and lower (blue) position of the flap; notice the concomitant conformational change of the Lys-78 side chain (upper right). Cgamma , Odelta -1, and Odelta -2 of Asp-184, refined in the ``normal'' conformation (indicated in blue) found in AMPPNP-, H7-, or H89-cAPK·PKI, have high B values in the H8-cAPK·PKI refinement. The unrefined extremely lowered position of the flap is shown in green.
[View Larger Version of this Image (32K GIF file)]

The adenosine binding site has been studied with lin-benzoadenine, where a C-6 ring separates the adenine five- and six-membered rings, and 1,N6-ethenoadenine nucleotides (37). The large Mg-lin-benzoadenine derivatives bind with affinities similar to MgADP or MgATP. Thus, it is not surprising that the isoquinolines are accepted in the adenine position. However, changes in the N-6 position, as for guanine nucleotides or 1,N6-ethenoadenine, appear to affect binding strongly. Bulky substitutions at N-6, as in the purine analogs olomoucine or isopentenyladenine, can cause completely different binding modes compared with adenosine, as observed in the cyclin-dependent protein kinase (40).

Conformational Flexibility of the Glycine Flap

In the molecular replacement solution of the structures of the H7-cAPK·PKI and H8-cAPK·PKI complexes, the glycine flap initially was modeled in a position very similar to the ternary AMPPNP-cAPK·PKI complex. Difference density, however, suggested a much more open conformation of the glycine flap. Remodeling indicated partial occupancy for two positions of the glycine flap with relatively high B values (Figs. 6 and 7). Both conformations are interrelated by a 14° rotation of the glycine flap about an axis through the Gly-50 and Val-57 Calpha atoms. This was observed in all crystals except H89-cAPK·PKI. Consequently, the side chain of Lys-78 also occupies two positions, one is compatible with an H bond to the Ser-53 carbonyl in the lower flap position, but would clash with the flap in its upper position. Very weak electron density in both H8-cAPK·PKI and in the H7-cAPK·PKI maps may suggest a third, much lower position of the glycine flap; however, artifacts cannot be excluded. While this low loop was not refined, there are no obvious steric restrictions for such a position of the glycine flap, which could contribute to inhibitor selectivity by enhancing the fit of the binding site. In the H89-cAPK·PKI crystal, in contrast, the glycine flap has clearly defined electron density and normal B values (Fig. 7), indicating dominance of a single upper position of the flap (Fig. 8).


Fig. 7. B values (in Å2) of the peptide backbone in the region of the glycine flap in the H inhibitor crystal structures. The B values for both refined positions of the glycine flap in the H7- and H8-cAPK·PKI crystals are given.
[View Larger Version of this Image (20K GIF file)]


Fig. 8. Stereo image of the H89 binding site. The van der Waals surface of the bromine is shown. H bonds to enzyme residues via water molecules are shown as dotted lines.
[View Larger Version of this Image (19K GIF file)]

Binding of H7

H7 has the lowest affinity and selectivity for cAPK of the three inhibitors (Table I). The structural position of the H7 isoquinoline rings resembles that of H8 and H89. In contrast to H8 and H89, however, the dihedral angle of the H7 sulfonyl group differs by an 86° rotation clockwise around the C-5-SO2 axis (Figs. 4A and 9). The electron density of the H7 inhibitor without any model bias is shown as an omit map in Fig. 10. The piperazine ring is in a chair conformation with an axial N-H bond at the N-17. The axial methyl group and the equatorial sulfonyl group are in cis, and the asymmetric carbon atom C-22 has the S enantiomer configuration. The N-17 in the piperazine ring shares a hydrogen with the backbone carbonyl of Glu-170 (Fig. 9). Together with the hydrogen bond of the isoquinoline nitrogen to the carbonyl of Val-123, H7 has two polar contacts and a total of 50 van der Waals contacts to enzyme atoms; two H bonds are formed with water molecules. One of them, Wat406, may contribute to H-7 binding by bridging the N-17 to the delta 1 oxygen of Asn-171.


Fig. 9. Stereo picture of H7 bound to the active site of the kinase. Hydrogen bonds are depicted in dotted lines.
[View Larger Version of this Image (24K GIF file)]


Fig. 10. Stereo image of inhibitor H7 (H7-cAPK·PKI) with electron density maps: the light blue maps show the final 2Fo-Fc map contoured at 1 sigma ; superimposed on the inhibitor is the green difference density Fo-Fc after the first cycle of protein refinement before modeling any inhibitor structure. The latter map thus lacks any history of model bias of the inhibitor. The strongest difference density peak matches the sulfur position, whereas the remaining peaks match the ring positions. Some distortion of the map at both rings may arise from a combination of small scale disorder and spurious effects from scattering from the sulfur atom.
[View Larger Version of this Image (97K GIF file)]

Binding of H8

The smallest inhibitor, H8, has intermediate affinity for cAPK (Table I); Fig. 4B shows its superposition with ATP. One of the SO2 oxygens (O-2) of the sulfonamide group superimposes roughly with the O-4' ring oxygen. O-1 is close to the amide of Gly-50, unfavorably oriented for a weak interaction (Fig. 5), which is impossible for H7 because of the differing dihedral angles at the sulfonyl groups. A water molecule (Wat-412) bridges one H8 sulfonyl oxygen to the carboxylate of Asp-184. Only one water molecule (Wat-424) makes contacts with N-4 amide. The N-17 of H8 makes H bond contacts to the backbone carbonyl of Glu-170 and to the carboxylate of Asp-184, an invariant residue and ligand of the high affinity metal ion in the AMPPNP-cAPK·PKI structure; in complex with H8, however, it is in an altered conformation. The N-17 of H8 is near (3.6 Å) the Odelta -1 of invariant Asn-171, the ligand of the second metal ion in the ternary AMPPNP-cAPK·PKI complex. The N-17, like the N-17 of H7, is bridged to the Odelta -1 oxygen of Asn-171 via water Wat-406. H8 shares three H bonds and 46 nonpolar Van der Waals contacts with enzyme atoms; in addition it has four polar and seven nonpolar contacts to water molecules. The larger number of polar contacts to the enzyme is consistent with its higher affinity for H8 than for H7.

In agreement with the structures, Hagiwara et al. (41) showed metal ion-independent binding of 1 mol/mol H8 to cAPK. They analyzed the effect of active site reagents upon binding of H8. Like MgATP, H8 efficiently protects the enzyme against modification by the nucleotide analog p-fluorosulfonylbenzoyl-5'-adenosine. In contrast to ATP, but similar to ADP, H8 is rather ineffective against the action of non-nucleotidic reagents such as 5,5'-dithiobis-(2-nitrobenzoic acid) and 7-chloro-4-nitro-2,1,3-benzoxadiazole or o-phthalaldehyde, which are known to inactivate the kinase by modifications on Cys-199 or Lys-72 (38). In the structures, H8 is 16 Å from Cys-199 and 8 Å from Lys-72. Bhatnagar et al. (42) used lin-benzoadenosine derivatives to analyze the nucleotide binding site of cAPK. Only lin-benzoadenosine, but not lin-benzo-ADP or lin-benzo-ATP binds to a catalytic subunit modified by p-fluorosulfonylbenzoyl-5'-adenosine, 7-chloro-4-nitro-2,1,3-benzoxadiazole, or 5,5'-dithiobis-(2-nitrobenzoic acid) (38). On the other hand, only AMP, but not MgADP or MgATP, is able to replace lin-benzoadenosine from the modified kinase, indicating similar binding sites for adenosine, lin-benzoadenosine, and for H8, distinct from the beta - and gamma -phosphate subsite, corresponding to the crystal structures. Slightly different behavior of lin-benzo-nucleotides has been observed in cGPK (39).

Binding of H89

The common parts of the H8 and the H89 molecules have very similar spatial structures and binding modes. Some differences are apparent, however (Fig. 8). The side chain of Thr-183 partially occupies two orientations, one in a position as in the ternary complex and the other as in the H8-PKI·cAPK co-crystal. H89 binding, in contrast to H8, did not cause a conformational change of Asp-184. The N-17 interacts with the carbonyl of Glu-170 as in both other inhibitors and, like N-17 of H8, is close to the side chain of Asn-171 (3.45 Å). A number of contacts are made via bridging water molecules. A central position is held by water Wat-424, which bridges both O-1 and N-4 of the sulfonamide to the side chain of Glu-127 and to the main chain carbonyl of Leu-49. Wat-413 bridges the N-17 to the side chains of Asn-171, Thr-183, and almost to Asp-184 (3.47 Å). The large bromocinnamoyl group extends H89 to roughly the size of an ATP molecule but cannot mimic any of the properties of a triphosphate. While the triphosphate group of ATP is tightly integrated into an extensive network of polar interactions with invariant and catalytic active site residues, including Lys-72, Asp-166, Lys-168, Asn-171, and Asp-184, none of these residues interacts directly with the bromocinnamoyl group of H89. Instead, the H89 side chain points away from the catalytic loop toward the glycine flap, fixing it into its upper position. The large bromine contributes to Van der Waals contacts. H89 has a total of 66 nonpolar Van der Waals contacts and two H bonds to enzyme atoms, in addition to five nonpolar and three polar interactions with water molecules. The high affinity of H89 compared with H8 is explained by the much larger number of Van der Waals contacts to the enzyme.

General Selectivity

The binding of the H inhibitors in the adenosine binding site raises the question why nucleotide binding proteins are not inhibited by the isoquinoline sulfonamides in general. Few data are available; there is little indication, however, for significant side effect inhibition of other enzymes. We visually inspected the adenosine binding sites of non-protein kinases in the Brookhaven Protein Data Bank (30). Most proteins seem to have no or incomplete and open binding pockets for the adenosine moiety; these enzymes primarily interact with the phosphoryl group or part of the adenosine derivative, making the binding of isoquinolinesulfonamide inhibitors unlikely. Among these proteins are actin (1atn), DNA-polymerase beta  (1bpe), fructose-1,6-bisphosphatase (1fbp), or phosphofructokinase (4pfk). Enzymes possessing an adenosine pocket may have little affinity for the isoquinoline derivatives if their binding site is more polar or sterically different from cAPK. Because of the flexible nature of biomolecules, steric effects are the most unreliable to predict. Enzymes with different X angles of their bound ribose may fall in this group as well as enzymes with atoms of the peptide backbone in spatial proximity to the purine, which could interfere with the somewhat larger isoquinoline. Examples are adenosine deaminase (1add), aspartyl-tRNA synthetase (1asz), adenylate kinase (ake), or glutaminyl-tRNA synthetase (1gtr). However, the actual binding mode may be difficult to predict.

Protein Kinase Selectivity

The crystal structures of two other kinases in an active conformation have been solved recently, protein kinase CK-1 (CKi-1) from Schizosaccharomyces pombe (43) and phosphorylase kinase gamma -subunit (PhKgamma ) from rabbit (44), allowing an evaluation of the potential for H inhibitor binding. The affinity of CK-1 for H7, H8, or H89 is lower than for cAPK (Table I); it is inhibited, however, by another isoquinolinesulfonyl inhibitor CKI-7. The ATP-binding sites of CK-1 and cAPK differ in several residues. The side chain of Met-120, which moves upon inhibitor binding in cAPK, is conservatively replaced by isoleucine in CKi-1. CKi-1 has a one-residue deletion. The residues Val-123-Ala-Gly-Gly are replaced by {Leu-88-Gly-89-Pro90}.3 This might narrow the adenine pocket, bringing {Leu-88} too close to the isoquinoline rings. The conservative replacements of Leu-49 and almost invariant Val-57 by isoleucine may be sterically unfavorable for the sulfonyl groups, while the extra methyl group of {Ile-26} is likely to clash with the aromatic ring in the H89 side chain and account for the low affinity for H89. CK-7 has a chloride in the 5-position and the sulfonamide in the 8-position. Assuming that the ring nitrogen makes a similar contact to the amide of {Leu-88}, CK-7 has to bind differently to CK-1.4

The Ki of H7 for PhKgamma is 47 µM, which is in the range of the Km for ATP in this enzyme (45, 46). The structural similarity between cAPK and PhKgamma is high. Superposition indicates very limited differences in the ATP-binding pocket. {Ile-87} in the position of Val-104 and {Phe-103} as a conservative replacement of Met-120 do not visibly interfere with the isoquinolines. However, the large number of Van der Waals interactions of Tyr-122 with the isoquinolines presumably cannot be achieved by {Leu-105}. This also applies to Phe-327, which has no substitute in PhKgamma . Both residues interact especially with the isoquinolines, as they have only very few contacts to ATP (Table III). PhKgamma has a serine in the position of Gly-55. Sterical conflicts with the bromocinnamoyl moiety of H89 appear possible.

The popularity of the inhibitor H7 results mainly from its ability to interfere with protein kinase C pathways, with an affinity for H7 half that of cAPK. H8 inhibits cAPK more strongly by a factor of 10. Looking for nonconserved residues in the ATP-binding site of PKCalpha from rat (20) compared with cAPK revealed very few differences. Thr-183 is alanine, and Leu-173 is methionine in some isoenzymes of PKC, which might result in a less tight fit of the pocket. Glu-127, responsible for substrate recognition in cAPK and almost in contact to the sulfonylamides, is an aspartate in PKC. Unless the backbone conformation of the enzyme changes, a preference of PKC for H7 is not apparent from these differences. A contribution to selectivity from outside the catalytic core appears possible. Phe-327 interacts with the isoquinoline rings in all three inhibitors; however, because of the rotated sulfonyl group of H7, the Phe-327 ring is in Van der Waals contact to it. Here is a region of potential interaction with PKC-specific residues.

Concluding Remarks

While the triphosphate subsite is highly conserved throughout the protein kinase family, a larger variability exists in the residues lining the adenosine pocket, the site which is used by the isoquinolinesulfonamide inhibitors. The finding that some residues are involved in isoquinoline binding to a larger extent than in purine binding (Table III) may help to explain that the binding constants vary between protein kinases much more for certain classes of inhibitors than for ATP. Residues from outside the conserved catalytic core, such as Phe-327, can also be of significance. In other protein kinases here is a potential site for selective interaction. As binding of the H inhibitors is remarkably similar in all three cases, the side chain of the inhibitors appears to be little responsible for the general mode of binding. This should facilitate the construction of inhibitor variants. Clearly, more crystal structures of other inhibitor complexes are needed to complete our understanding of the binding parameters in the ATP-binding sites of protein kinases.

In contrast to many other enzymes, the protein kinase has a well defined and relatively hydrophobic binding pocket for the purine. During evolution protein kinases have optimized their active site to accommodate many different substrate proteins. This has led to the development of an extremely buried nucleotide binding site and reduced sterical restrictions at the peptide site (34). The drawback of such an optimized peptide binding site is that the buried ADP product can only slowly be exchanged for ATP (22, 47). The relative hydrophobicity of the adenine pocket might reduce the binding forces for the purine to fasten nucleotide exchange.


FOOTNOTES

*   This work was supported by the Deutsche Forschungsgemeinschaft. The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§   To whom correspondence should be addressed: 0210 Dept. for Pathochemistry, German Cancer Research Center, INF 280, D-69120 Heidelberg, Germany. Tel. 49 6221 423257; Fax: 49 6221 423259; E-mail: bossemeyer{at}dkfz-heidelberg.de.
1   The abbreviations used are: cAPK, cAMP-dependent protein kinase; H7, 1-(5-isoquinolinesulfonyl)-2-methylpiperazine; H8, N-[2-(methylamino)ethyl]-5-isoquinolinesulfonamide; H89, N-[2-(p-Bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide; CKi-1, truncated form of protein kinase CK-1; CKI-7, N-[2-aminoethyl]-5-chloro-isoquinoline-8-sulfonamide; MES, 4-morpholineethanesulfonic acid; Chaps, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid; BisTris, 2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)-propane-1,3-diol; PKI, protein kinase inhibitor.
2   Structure factors and atomic coordinates of H7-cAPK·PKI, H8-cAPK·PKI, and H89-cAPK·PKI (codes 1YDR, 1YDS, and 1YDT) have been submitted to the Brookhaven Protein Data Bank. Before release they will be available on request via E-mail from bossemeyer{at}dkfz-heidelberg.de.
3   For more clarity residue numbers from enzymes other than cAPK are in braces.
4   During the final stages of preparation of this manuscript the structure of CK-7 in binary complex with protein kinase CKi-1 (R.-M. Xu, G. Carmel, J. Kuret, X. Cheng) became available from the Protein Data Bank (2CSN), showing, as was predicted here, somewhat different orientations of the isoquinoline and its side chain, which does not contact the carbonyl of {Asp-135} (Glu-170).

Acknowledgments

We are grateful to Paul Jedrzejewski for mass spectrometry of the enzyme. We thank Louise Johnson for coordinates of PhKgamma and Xiaodong Cheng for coordinates of CKi-1. The bacterial expression system was used with the kind permission of Stanley Tabor, Harvard Medical School (pT7-7), and F. William Studier, Brookhaven National Laboratory (BL21(DE3)).


REFERENCES

  1. Hidaka, H., Inagaki, M., Kawamoto, S., Sasaki, Y. (1984) Biochemistry 23, 5036-5041 [CrossRef][Medline] [Order article via Infotrieve]
  2. Chijiwa, T., Mishima, A., Hagiwara, M., Sano, M., Hayashi, K., Inoue, T., Naito, K., Toshioka, T., Hidaka, H. (1990) J. Biol. Chem. 265, 5267-5272 [Abstract/Free Full Text]
  3. Denisenko, N., Burighel, P., Citi, S. (1994) J. Cell. Sci. 107, 969-981 [Abstract]
  4. Malinow, R., Schulman, H., Tsien, R. W. (1989) Science 245, 862-866 [Abstract/Free Full Text]
  5. Malenka, R. C., Kauer, J. A., Perkel, D. J., Mauk, M. D., Kelly, P. T., Nicoll, R. A., Waxham, M. N. (1989) Nature 340, 554-557 [CrossRef][Medline] [Order article via Infotrieve]
  6. Dubois, M.-F., Nguyen, V. T., Bellier, S., Bensaude, O. (1994) J. Biol. Chem. 269, 13331-13336 [Abstract/Free Full Text]
  7. Konda, Y., Gantz, I., DelValle, J., Shimoto, Y., Miwa, H., Yamada, T. (1994) J. Biol. Chem. 269, 13162-13166 [Abstract/Free Full Text]
  8. Guizouarn, H., Borgese, F., Pellissier, B., Garcia-Romeu, F., Motais, R. (1993) J. Biol. Chem. 268, 8632-8639 [Abstract/Free Full Text]
  9. Findik, D., Song, Q., Hidaka, H., Lavin, M. (1995) J. Cell. Biochem. 57, 12-21 [CrossRef][Medline] [Order article via Infotrieve]
  10. Traganos, F., Knuttihotz, J., Hotz, M., Gorczyca, W., Ardelt, B., Darzynkiewicz, Z. (1993) Int. J. Oncol. 2, 47-59
  11. Felipo, V., Minana, M. D., Cabedo, H., Perezminguez, F., Llombartbosch, A., Grisolia, S. (1994) Eur. J. Can. 30, 525-527
  12. May, W. S., Tyler, P. G., Ito, T., Armstrong, D. K., Qatsha, K. A., Davidson, N. E. (1994) J. Biol. Chem. 269, 26865-26870 [Abstract/Free Full Text]
  13. Honma, Y., Okabe Kado, J., Kasukabe, T., Hozumi, M., Kajigaya, S., Suda, T., Miura, Y. (1991) Cancer Res. 51, 4649-4655 [Abstract/Free Full Text]
  14. Kim, S. H., Park, J. I., Chung, B. S., Kang, C. D., Hidaka, H. (1993) Cancer Lett. 74, 37-41 [CrossRef][Medline] [Order article via Infotrieve]
  15. Morgan, D. O., Debondt, H. L. (1994) Curr. Opin. Cell Biol. 6, 239-246 [CrossRef][Medline] [Order article via Infotrieve]
  16. Goldsmith, E. J., Cobb, M. H. (1994) Curr. Opin. Struct. Biol. 4, 833-840 [CrossRef][Medline] [Order article via Infotrieve]
  17. Bossemeyer, D. (1995) FEBS Lett. 369, 57-61 [CrossRef][Medline] [Order article via Infotrieve]
  18. Taylor, S. S., Radzioandzelm, E. (1994) Structure 2, 345-355 [Medline] [Order article via Infotrieve]
  19. Cox, S., Radzioandzelm, E., Taylor, S. S. (1994) Curr. Opin. Struct. Biol. 4, 893-901 [CrossRef][Medline] [Order article via Infotrieve]
  20. Hanks, S. K., Quinn, A. M. (1991) Methods Enzymol. 200, 38-81 [Medline] [Order article via Infotrieve]
  21. Zheng, J. H., Knighton, D. R., ten-Eyck, L. F., Karlsson, R., Xuong, N., Taylor, S. S., Sowadski, J. M. (1993) Biochemistry 32, 2154-2161 [CrossRef][Medline] [Order article via Infotrieve]
  22. Bossemeyer, D., Engh, R. A., Kinzel, V., Ponstingl, H., Huber, R. (1993) EMBO J. 12, 849-859 [Medline] [Order article via Infotrieve]
  23. Wiemann, S., Kinzel, V., Pyerin, W. (1992) Biochim. Biophys. Acta 1171, 93-96 [Medline] [Order article via Infotrieve]
  24. Olsen, S. R., Uhler, M. D. (1989) J. Biol. Chem. 264, 18662-18666 [Abstract/Free Full Text]
  25. Herberg, F. W., Bell, S. M., Taylor, S. S. (1993) Protein Eng. 6, 771-777 [Abstract/Free Full Text]
  26. Knighton, D. R., Bell, S. M., Zheng, J., TenEick, L. F., Xuong, N.-H., Taylor, S. S., Sowadski, J. M. (1993) Acta Crystallogr. Sect. D 49, 362-365
  27. Brunger, A. T. (1988) J. Mol. Biol. 203, 803-816 [CrossRef][Medline] [Order article via Infotrieve]
  28. Cheng, H.-C., Kemp, B. E., Pearson, R. B., Smith, A. J., Misconi, L., Van Patten, S. M., Walsh, D. A. (1986) J. Biol. Chem. 261, 989-992 [Abstract/Free Full Text]
  29. Knighton, D. R., Zheng, J. H., Ten-Eyck, L. F., Ashford, V. A., Xuong, N. H., Taylor, S. S., Sowadski, J. M. (1991) Science 253, 407-414 [Abstract/Free Full Text]
  30. Bernstein, F. C., Koetzle, T. F., Williams, G. J. B., Meyer, E. F., Jr., Price, M. D., Rogers, J. R., Kennard, O., Shimanouchi, T., Tasumi, M. (1977) J. Mol. Biol. 112, 535-542 [Medline] [Order article via Infotrieve]
  31. Jones, T. A., You, J. Y., Cowan, S. W., Kjeldgaard, M. (1991) Acta Crystallogr. Sect. A 47, 110-119
  32. Zheng, J. H., Knighton, D. R., Xuong, N. H., Taylor, S. S., Sowadski, J. M., Teneyck, L. F. (1993) Protein Sci. 2, 1559-1573 [Medline] [Order article via Infotrieve]
  33. Yonemoto, W., Garrod, S. M., Bell, S. M., Taylor, S. S. (1993) J. Biol. Chem. 268, 18626-18632 [Abstract/Free Full Text]
  34. Bossemeyer, D. (1994) Trends Biochem. Sci. 19, 201-205 [CrossRef][Medline] [Order article via Infotrieve]
  35. Whitehouse, S., Walsh, D. A. (1983) J. Biol. Chem. 258, 3682-3692 [Abstract/Free Full Text]
  36. Herberg, F. W., Taylor, S. S. (1993) Biochemistry 32, 14015-14022 [CrossRef][Medline] [Order article via Infotrieve]
  37. Hartl, F. T., Roskoski, R., Jr., Rosendahl, M. S., Leonard, N. J. (1983) Biochemistry 22, 2347-2352 [CrossRef][Medline] [Order article via Infotrieve]
  38. Bhatnagar, D., Hartl, F. T., Roskowski, R., Jr., Lessor, R. A., Leonard, N. J. (1984) Biochemistry 23, 4350-4357 [CrossRef][Medline] [Order article via Infotrieve]
  39. Bhatnagar, D., Glass, D. B., Roskoski, R., Jr., Lessor, R. A, Leonard, N. J. (1985) Biochemistry 24, 1122-1129 [CrossRef][Medline] [Order article via Infotrieve]
  40. Schulze-Gahmen, U., Brandsen, J., Jones, H. D., Morgan, D. O., Meijer, L., Vesely, J., Kim, S.-H. (1995) Proteins Struct. Funct. Genet. 22, 378-391 [CrossRef][Medline] [Order article via Infotrieve]
  41. Hagiwara, M., Inagaki, M., Hidaka, H. (1987) Mol. Pharmacol. 31, 523-528 [Abstract]
  42. Bhatnagar, D., Roskoski, R., Jr., Rosendahl, M. S., Leonard, N. J. (1983) Biochemistry 22, 6310-6317 [CrossRef][Medline] [Order article via Infotrieve]
  43. Xu, R. M., Carmel, G., Sweet, R. M., Kuret, J., Cheng, X. (1995) EMBO J. 14, 1015-1023 [Medline] [Order article via Infotrieve]
  44. Owen, D. J., Noble, M. E. M., Garman, E. F., Papageorgiou, A. C., Johnson, L. N. (1995) Structure 3, 467-482 [Medline] [Order article via Infotrieve]
  45. Elliott, L. H., Wilkinson, S. E., Sedgwick, A. D., Hill, C. H., Lawton, G., Davis, P. D., Nixon, J. S. (1990) Biochem. Biophys. Res. Commun. 171, 148-154 [CrossRef][Medline] [Order article via Infotrieve]
  46. Lee, J. H., Maeda, S., Angelos, K. L., Kamita, S. G., Ramachandran, C., Walsh, D. A. (1992) Biochemistry 31, 10616-10625 [CrossRef][Medline] [Order article via Infotrieve]
  47. Adams, J. A., Taylor, S. S. (1992) Biochemistry 31, 8516-8522 [CrossRef][Medline] [Order article via Infotrieve]
  48. Kraulis, P. J. (1991) J. Appl. Crystallogr. 24, 946-950 [CrossRef]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Sci SignalHome page
A. J. Murray
Pharmacological PKA Inhibition: All May Not Be What It Seems
Sci. Signal., June 3, 2008; 1(22): re4 - re4.
[Abstract] [Full Text] [PDF]


Home page
Microbiol. Mol. Biol. Rev.Home page
C. R. Pigott and D. J. Ellar
Role of Receptors in Bacillus thuringiensis Crystal Toxin Activity
Microbiol. Mol. Biol. Rev., June 1, 2007; 71(2): 255 - 281.
[Abstract] [Full Text] [PDF]


Home page
J. Neurophysiol.Home page
C. Lavialle-Defaix, H. Gautier, A. Defaix, B. Lapied, and F. Grolleau
Differential Regulation of Two Distinct Voltage-Dependent Sodium Currents by Group III Metabotropic Glutamate Receptor Activation in Insect Pacemaker Neurons
J Neurophysiol, November 1, 2006; 96(5): 2437 - 2450.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Bonn, S. Herrero, C. B. Breitenlechner, A. Erlbruch, W. Lehmann, R. A. Engh, M. Gassel, and D. Bossemeyer
Structural Analysis of Protein Kinase A Mutants with Rho-kinase Inhibitor Specificity
J. Biol. Chem., August 25, 2006; 281(34): 24818 - 24830.
[Abstract] [Full Text] [PDF]


Home page
J AndrolHome page
J. Baumber and S. A. Meyers
Changes in Membrane Lipid Order With Capacitation in Rhesus Macaque (Macaca mulatta) Spermatozoa
J Androl, July 1, 2006; 27(4): 578 - 587.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
X. Zhang, M. Candas, N. B. Griko, R. Taussig, and L. A. Bulla Jr.
A mechanism of cell death involving an adenylyl cyclase/PKA signaling pathway is induced by the Cry1Ab toxin of Bacillus thuringiensis
PNAS, June 27, 2006; 103(26): 9897 - 9902.
[Abstract] [Full Text] [PDF]


Home page
J AndrolHome page
J. Baumber and S. A. Meyers
Hyperactivated Motility in Rhesus Macaque (Macaca mulatta) Spermatozoa
J Androl, May 1, 2006; 27(3): 459 - 468.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. J. Loza, S. Foster, S. P. Peters, and R. B. Penn
Beta-agonists modulate T-cell functions via direct actions on type 1 and type 2 cells
Blood, March 1, 2006; 107(5): 2052 - 2060.
[Abstract] [Full Text] [PDF]


Home page
J. Gen. Virol.Home page
N. Kucic, H. Mahmutefendic, and P. Lucin
Inhibition of protein kinases C prevents murine cytomegalovirus replication
J. Gen. Virol., August 1, 2005; 86(8): 2153 - 2161.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
Y. Luo, A. R. Shoemaker, X. Liu, K. W. Woods, S. A. Thomas, R. de Jong, E. K. Han, T. Li, V. S. Stoll, J. A. Powlas, et al.
Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo
Mol. Cancer Ther., June 1, 2005; 4(6): 977 - 986.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
D. L. Clarke, M. G. Belvisi, S. J. Smith, E. Hardaker, M. H. Yacoub, K. K. Meja, R. Newton, D. M. Slater, and M. A. Giembycz
Prostanoid receptor expression by human airway smooth muscle cells and regulation of the secretion of granulocyte colony-stimulating factor
Am J Physiol Lung Cell Mol Physiol, February 1, 2005; 288(2): L238 - L250.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
D. L. Clarke, M. G. Belvisi, E. Hardaker, R. Newton, and M. A. Giembycz
E-Ring 8-Isoprostanes Are Agonists at EP2- and EP4-Prostanoid Receptors on Human Airway Smooth Muscle Cells and Regulate the Release of Colony-Stimulating Factors by Activating cAMP-Dependent Protein Kinase
Mol. Pharmacol., February 1, 2005; 67(2): 383 - 393.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. G. Rondaij, E. Sellink, K. A. Gijzen, J. P. ten Klooster, P. L. Hordijk, J. A. van Mourik, and J. Voorberg
Small GTP-Binding Protein Ral Is Involved in cAMP-Mediated Release of von Willebrand Factor From Endothelial Cells
Arterioscler. Thromb. Vasc. Biol., July 1, 2004; 24(7): 1315 - 1320.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Gassel, C. B. Breitenlechner, N. Konig, R. Huber, R. A. Engh, and D. Bossemeyer
The Protein Kinase C Inhibitor Bisindolyl Maleimide 2 Binds with Reversed Orientations to Different Conformations of Protein Kinase A
J. Biol. Chem., May 28, 2004; 279(22): 23679 - 23690.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
K. K. Meja, M. C. Catley, L. M. Cambridge, P. J. Barnes, H. Lum, R. Newton, and M. A. Giembycz
Adenovirus-Mediated Delivery and Expression of a cAMP-Dependent Protein Kinase Inhibitor Gene to BEAS-2B Epithelial Cells Abolishes the Anti-Inflammatory Effects of Rolipram, Salbutamol, and Prostaglandin E2: A Comparison with H-89
J. Pharmacol. Exp. Ther., May 1, 2004; 309(2): 833 - 844.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
H. Vankayalapati, D. J. Bearss, J. W. Saldanha, R. M. Munoz, S. Rojanala, D. D. Von Hoff, and D. Mahadevan
Targeting Aurora2 Kinase in Oncogenesis: A Structural Bioinformatics Approach to Target Validation and Rational Drug Design
Mol. Cancer Ther., March 1, 2003; 2(3): 283 - 294.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Cottom, L. M. Salvador, E. T. Maizels, S. Reierstad, Y. Park, D. W. Carr, M. A. Davare, J. W. Hell, S. S. Palmer, P. Dent, et al.
Follicle-stimulating Hormone Activates Extracellular Signal-regulated Kinase but Not Extracellular Signal-regulated Kinase Kinase through a 100-kDa Phosphotyrosine Phosphatase
J. Biol. Chem., February 21, 2003; 278(9): 7167 - 7179.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
R. M. Rao, Y. Jo, S. Leers-Sucheta, H. S. Bose, W. L. Miller, S. Azhar, and D. M. Stocco
Differential Regulation of Steroid Hormone Biosynthesis in R2C and MA-10 Leydig Tumor Cells: Role of SR-B1-Mediated Selective Cholesteryl Ester Transport
Biol Reprod, January 1, 2003; 68(1): 114 - 121.
[Abstract] [Full Text] [PDF]


Home page
J Biomol ScreenHome page
I. Vainshtein, S. Silveria, P. Kaul, R. Rouhani, R. M. Eglen, and J. Wang
A High-Throughput, Nonisotopic, Competitive Binding Assay for Kinases Using Nonselective Inhibitor Probes (ED-NSIPTM)
J Biomol Screen, December 1, 2002; 7(6): 507 - 514.
[Abstract] [PDF]


Home page
Mol. Cell. Biol.Home page
C. Hauser, B. Schuettengruber, S. Bartl, G. Lagger, and C. Seiser
Activation of the Mouse Histone Deacetylase 1 Gene by Cooperative Histone Phosphorylation and Acetylation
Mol. Cell. Biol., November 15, 2002; 22(22): 7820 - 7830.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
L. M. Salvador, E. Maizels, D. B. Hales, E. Miyamoto, H. Yamamoto, and M. Hunzicker-Dunn
Acute Signaling by the LH Receptor Is Independent of Protein Kinase C Activation
Endocrinology, August 1, 2002; 143(8): 2986 - 2994.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. M. Salvador, Y. Park, J. Cottom, E. T. Maizels, J. C. R. Jones, R. V. Schillace, D. W. Carr, P. Cheung, C. D. Allis, J. L. Jameson, et al.
Follicle-stimulating Hormone Stimulates Protein Kinase A-mediated Histone H3 Phosphorylation and Acetylation Leading to Select Gene Activation in Ovarian Granulosa Cells
J. Biol. Chem., October 19, 2001; 276(43): 40146 - 40155.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. J. Staples, M. Bergmann, K. Tomita, M. D. Houslay, I. McPhee, P. J. Barnes, M. A. Giembycz, and R. Newton
Adenosine 3',5'-Cyclic Monophosphate (cAMP)-Dependent Inhibition of IL-5 from Human T Lymphocytes Is Not Mediated by the cAMP-Dependent Protein Kinase A
J. Immunol., August 15, 2001; 167(4): 2074 - 2080.
[Abstract] [Full Text] [PDF]


Home page
JCBHome page
R. Pepperkok, A. Hotz-Wagenblatt, N. Konig, A. Girod, D. Bossemeyer, and V. Kinzel
Intracellular Distribution of Mammalian Protein Kinase A Catalytic Subunit Altered by Conserved Asn2 Deamidation
J. Cell Biol., February 21, 2000; 148(4): 715 - 726.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. S. Grewal, A. M. Horgan, R. D. York, G. S. Withers, G. A. Banker, and P. J. S. Stork
Neuronal Calcium Activates a Rap1 and B-Raf Signaling Pathway via the Cyclic Adenosine Monophosphate-dependent Protein Kinase
J. Biol. Chem., February 4, 2000; 275(5): 3722 - 3728.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Pesu, K. Takaluoma, S. Aittomaki, A. Lagerstedt, K. Saksela, P. E. Kovanen, and O. Silvennoinen
Interleukin-4-induced transcriptional activation by Stat6 involves multiple serine/threonine kinase pathways and serine phosphorylation of Stat6
Blood, January 15, 2000; 95(2): 494 - 502.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Amano, K. Chihara, N. Nakamura, T. Kaneko, Y. Matsuura, and K. Kaibuchi
The COOH Terminus of Rho-kinase Negatively Regulates Rho-kinase Activity
J. Biol. Chem., November 5, 1999; 274(45): 32418 - 32424.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
H. Lum, H. A. Jaffe, I. T. Schulz, A. Masood, A. RayChaudhury, and R. D. Green
Expression of PKA inhibitor (PKI) gene abolishes cAMPmediated protection to endothelial barrier dysfunction
Am J Physiol Cell Physiol, September 1, 1999; 277(3): C580 - C588.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
R. B. Penn, J.-L. Parent, A. N. Pronin, R. A. Panettieri Jr., and J. L. Benovic
Pharmacological Inhibition of Protein Kinases in Intact Cells: Antagonism of Beta Adrenergic Receptor Ligand Binding by H-89 Reveals Limitations of Usefulness
J. Pharmacol. Exp. Ther., February 1, 1999; 288(2): 428 - 437.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
M. Nishio, Y. Watanabe, and H. Hidaka
HMN-1180, a Small Molecule Inhibitor of Neuronal Nitric Oxide Synthase
J. Pharmacol. Exp. Ther., December 1, 1998; 287(3): 1063 - 1067.
[Abstract] [Full Text]


Home page
Mol. Pharmacol.Home page
X. Wang and T. J. Murphy
Inhibition of Cyclic AMP-Dependent Kinase by Expression of a Protein Kinase Inhibitor/Enhanced Green Fluorescent Fusion Protein Attenuates Angiotensin II-Induced Type 1 AT1 Receptor mRNA Down-Regulation in Vascular Smooth Muscle Cells
Mol. Pharmacol., September 1, 1998; 54(3): 514 - 524.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
V. A. Boundy, J. Chen, and E. J. Nestler
Regulation of cAMP-Dependent Protein Kinase Subunit Expression in CATH.a and SH-SY5Y Cells
J. Pharmacol. Exp. Ther., August 1, 1998; 286(2): 1058 - 1065.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
D. M. Daigle, G. A. McKay, and G. D. Wright
Inhibition of Aminoglycoside Antibiotic Resistance Enzymes by Protein Kinase Inhibitors
J. Biol. Chem., October 3, 1997; 272(40): 24755 - 24758.
[Abstract] [Full Text] [PDF]


Home page
ScienceHome page
M. Mohammadi, G. McMahon, L. Sun, C. Tang, P. Hirth, B. K. Yeh, S. R. Hubbard, and J. Schlessinger
Structures of the Tyrosine Kinase Domain of Fibroblast Growth Factor Receptor in Complex with Inhibitors
Science, May 9, 1997; 276(5314): 955 - 960.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
N. Mashhoon, A. J. DeMaggio, V. Tereshko, S. C. Bergmeier, M. Egli, M. F. Hoekstra, and J. Kuret
Crystal Structure of a Conformation-selective Casein Kinase-1 Inhibitor
J. Biol. Chem., June 23, 2000; 275(26): 20052 - 20060.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Tomas-Zuber, J.-L. Mary, and W. Lesslauer
Control Sites of Ribosomal S6 Kinase B and Persistent Activation through Tumor Necrosis Factor
J. Biol. Chem., July 28, 2000; 275(31): 23549 - 23558.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. M. Gowri, T. C. Ganguly, J. Cao, M. N. Devalaraja, B. Groner, and M. Vore
Conversion of Threonine 757 to Valine Enhances Stat5a Transactivation Potential
J. Biol. Chem., March 23, 2001; 276(13): 10485 - 10491.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Engh, R. A.
Right arrow Articles by Bossemeyer, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Engh, R. A.
Right arrow Articles by Bossemeyer, D.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 1996 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement